GLSI: Greenwich LifeSciences Inc Price/Earnings to Growth Multiple

Symbol and logo of brand Greenwich LifeSciences Inc (GLSI)

Risks of delays in the Phase III Flamingo-01 trials are weighing on quotes for Greenwich LifeSciences (GLSI), and while monitoring the PEG ratio chart on GURU.Markets, we note that the value 0.00 serves as a baseline indicator of undervaluation. Success is predicated on the outsourcing of vaccine production in Texas and high brand trust following breakthrough tests in the fight against breast cancer recurrence.

Price/Earnings to Growth Ratio: Greenwich LifeSciences Inc (GLSI) for 07/04/2022 - 11/13/2026

Analytical breakdowns for Greenwich LifeSciences (GLSI)

- share price and consensus valuation forecast:
Price Performance Chart Greenwich LifeSciences Inc.|GLSI - Analyst Consensus Forecast
- market capitalization information:
Market Valuation Greenwich LifeSciences, Inc|GLSI - Enterprise Value
- book value of equity indicators:
Book Value per Share Greenwich LifeSciences|GLSI - Company Book Value|Capitalization to Book Value Ratio greenwichlifesciences.com|GLSI - Company Total Assets
- debt obligations and liquidity statistics:
Total Debt to Equity Ratio Greenwich LifeSciences|GLSI - Long-Term Debt to Capital|Current Liabilities to Capital greenwichlifesciences.com|GLSI - Company Debts|Debt to Net Assets Ratio Greenwich LifeSciences, Inc|GLSI - Company Long-Term Debts|Short-Term Indebtedness Greenwich LifeSciences|Intermediate Coverage Ratio greenwichlifesciences.com
- company profitability and valuation multiples indicators:
GLSI - Net Profit|Expected Net Profit Greenwich LifeSciences|GLSI - P/E Multiple|Projected Price to Earnings Ratio Greenwich LifeSciences Inc|GLSI - Price/Earnings to Growth Ratio|Enterprise Value to Operating Income Before Depreciation Greenwich LifeSciences, Inc|GLSI - Operating profit before deduction of amortization|Net earnings per share for the last 12 months Greenwich LifeSciences|GLSI - Net earnings per share (EPS TTM)|Year-over-year net earnings per share change for the last twelve months greenwichlifesciences.com|GLSI - Earnings growth in current year|Expected earnings per share growth for next year Greenwich LifeSciences
Fundamental company analysis:Greenwich LifeSciences Inc., GLSI
Original product of Greenwich LifeSciences, Inc

For Greenwich LifeSciences (GLSI), a company focused on the commercialization of cancer immunotherapy, the PEG ratio trend reflects the balance between market value and the pace of profit expansion. This indicator compares the current P/E multiple with earnings growth rates, where a value below one signals that the asset is undervalued relative to its fundamental potential and future innovation monetization cycles.

Competing companies

OLMA (Olema Pharmaceuticals, Inc.) - Growth-Adjusted Payback Ratio|PEG Multiple PBYI (Puma Biotechnology, Inc.)|ZNTL - Price/Earnings to Growth Multiple|MacroGenics, Inc. - PEG Multiple|PSTV - PEG Multiple|processapharmaceuticals.com (PCSA) - Price/Earnings to Growth Ratio|Growth-Adjusted P/E Ratio EGRX